CEO Julia Marie Eastland buys 28,500 shares at $1.73 amid cluster buy; stock down -89.9% from 52-week high.
CEO Julia Marie Eastland purchased 28,500 shares at $1.73 on 2025-01-31 while the stock trades at $1.63 current price, representing a -89.9% decline from the 52-week high of $16.13. This transaction occurred as part of a cluster buy pattern, with 2 other insiders also purchasing within the past 14 days. The company's fundamentals show acute distress: Revenue of $0.00 in the latest quarter and a net loss of $-40,158,000.00 over the most recent full fiscal year, reflecting a pre-revenue biotech model with substantial cash burn. The CEO's acquisition of an initial position (0 to 28,500 shares) coinciding with coordinated insider buying at deeply depressed valuations merits scrutiny as a factual matter, particularly given the magnitude of the stock decline and the company's loss profile.